Leerink Partnrs Issues Pessimistic Outlook for KLRS Earnings

Kalaris Therapeutics Inc. (NASDAQ:KLRS) – Research analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for Kalaris Therapeutics in a report issued on Monday, November 17th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($0.68) per share for the quarter, down from their previous estimate of ($0.67).

Several other analysts have also issued reports on the company. Piper Sandler set a $3.00 target price on Kalaris Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. Citizens Jmp assumed coverage on shares of Kalaris Therapeutics in a research note on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective for the company. Citigroup began coverage on shares of Kalaris Therapeutics in a report on Monday, November 3rd. They set an “outperform” rating on the stock. Wall Street Zen downgraded shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Raymond James Financial began coverage on shares of Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Kalaris Therapeutics Price Performance

Shares of Kalaris Therapeutics stock opened at $6.68 on Thursday. The company has a market cap of $124.92 million, a price-to-earnings ratio of -1.77 and a beta of 0.42. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $14.63. The firm’s 50-day moving average price is $5.17.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.02.

Institutional Investors Weigh In On Kalaris Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in Kalaris Therapeutics in the 2nd quarter worth $65,000. Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics during the third quarter worth about $231,000. Belpointe Asset Management LLC purchased a new stake in shares of Kalaris Therapeutics during the third quarter worth about $231,000. Johnson Financial Group Inc. bought a new stake in shares of Kalaris Therapeutics in the third quarter worth about $58,000. Finally, Bridgeway Capital Management LLC purchased a new position in Kalaris Therapeutics during the 3rd quarter valued at about $130,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.